PDS Biotechnology Corporation
NASDAQ:PDSBBiotechnology
+$0.01 today
- Market cap
- $51.58M
- Beta
- 1.56
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.60
Volume 5.25M
Average 1.04M
PDSB Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
PDS Biotechnology CorporationNASDAQ: PDSB
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation outflow shrinks to $0
Q1 FY2026 stock-based compensation was $0, compared with $1.25M a year earlier. Trailing-twelve-month stock-based compensation was -$1.79B. Over 3 fiscal years it compounded at +824.6% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$448.35M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 4.11B USD
- Year-over-year change
- +59866.3%
- 4-year CAGR
- +462.2%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.11B | +59866.3% |
| FY2024 | 2024-12-31 | 6.85M | -10.1% |
| FY2023 | 2023-12-31 | 7.61M | +46.5% |
| FY2022 | 2022-12-31 | 5.2M | +26.4% |
| FY2021 | 2021-12-31 | 4.11M | — |
Stock-Based Compensation vs competitors
How PDSB compares with its peers on the latest reported figures
- PDSB's LTM Mar 2026 stock-based compensation of $1.79B is the largest of the 6 companies compared; the peer median is $1.48M.
- Its year-over-year change of -27809.6% is the lowest of 6, against a peer median of -62.7%.
- Over three fiscal years its annual growth of +824.6% compares with a peer median of +48.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.79B | -27809.6% | +824.6% | — | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $11.67M | +86.0% | +523.5% | — |
| LTM Mar 2026 | $6.49M | +5.8% | -6.3% | 12.1% | |
| LTM Mar 2026 | $1.48M | -62.7% | +481.3% | — | |
| LTM Mar 2026 | $579K | -107.3% | +11.5% | — | |
| LTM Jun 2026 | $237K | -98.0% | +48.7% | 0.7% | |
| Peer median (excluding PDSB) | $1.48M | -62.7% | +48.7% | 6.4% | |
Competitors are the stored peer set for PDSB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (16.92M) | (40.85M) | (42.94M) | (37.61M) | (34.5B) |
| Depreciation & Amortization | 5.36K | 86 | 17.36K | 21.11K | 1.55B |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.11M | 5.2M | 7.61M | 6.85M | 4.11B |
| Change in Working Capital | 75.82K | 4.47M | (199.28K) | (5.75M) | (382.97K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (105.82K) | (90.12K) | 5.76M | (5.3M) | 1.89M |
| Other Working Capital | 181.64K | 4.57M | (5.96M) | (453.77K) | (2.27M) |
| Other Non-Cash Items | 241.03K | 5.47M | 1.87M | 1.46M | 1.08B |
| Operating Cash Flow | (12.49M) | (25.71M) | (33.64M) | (35.03M) | (27.75B) |
| Capital Expenditures | 0 | 0 | 0 | (29K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | (29K) | 0 |
| Debt Repayment | 0 | 25M | (59.3K) | (3.18M) | (7.56M) |
| Common Stock Issued | 48.54M | 9.86M | 16.13M | 22.6M | 20.34M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 344.13K | (568.87K) | 308.94K | 774.09K | 12.76B |
| Financing Cash Flow | 48.89M | 34.29M | 16.38M | 20.19M | 12.77B |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 36.4M | 8.58M | (17.26M) | (14.87M) | (14.98B) |
| Free Cash Flow | (12.49M) | (25.71M) | (33.64M) | (35.06M) | (27.75B) |
PDS Biotechnology Corporation
NASDAQ:PDSB
Intrinsic Alpha fair value
Locked
Current Price
$0.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.